Literature DB >> 12883707

VHL tumor suppressor gene: its mutation and protein level in renal cell carcinoma.

Hisashi Tsutsumi1, Chikara Miyamoto, Yasuhiro Furuichi, Miki Yoshiike, Shiari Nozawa, Teruaki Iwamoto.   

Abstract

In this study, we identified mutations in the von Hippel-Lindau gene (VHL) in patients with sporadic clear cell renal carcinoma and analyzed the relationship between these VHL mutations and VHL protein (pVHL) expression levels. Analysis of VHL coding region mutations by direct polymerase chain reaction in 39 patients with clear cell renal carcinoma, who had all undergone radical nephrectomy, revealed heterozygous mutations in 7 (17.9%) of the 39 patients, including 2 novel mutations. Analysis of the levels of pVHL expression in tumor tissue samples from the 7 patients with mutations by Western blot analysis demonstrated that pVHL was not expressed in 3 patients, and that 3 subjects expressed about 50%, and 1 was similar to the normal level. These results suggest that the 3 patients who did not express pVHL had both mutation and loss of heterozygosity, and that the 3 patients who expressed about 50% of the normal pVHL level had heterozygous mutations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12883707

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

1.  Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma.

Authors:  Alison C Young; Rachel A Craven; Dena Cohen; Claire Taylor; Christopher Booth; Patricia Harnden; David A Cairns; Dewi Astuti; Walter Gregory; Eamonn R Maher; Margaret A Knowles; Adrian Joyce; Peter J Selby; Rosamonde E Banks
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

2.  Expression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosa.

Authors:  Antti-J Kivela; Seppo Parkkila; Juha Saarnio; Tuomo-J Karttunen; Jyrki Kivela; Anna-Kaisa Parkkila; Maria Bartosova; Vojtech Mucha; Michal Novak; Abdul Waheed; William-S Sly; Hannu Rajaniemi; Silvia Pastorekova; Jaromir Pastorek
Journal:  World J Gastroenterol       Date:  2005-05-07       Impact factor: 5.742

3.  Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells.

Authors:  S Mahajan; V Dammai; T Hsu; A S Kraft
Journal:  Carcinogenesis       Date:  2008-06-09       Impact factor: 4.944

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.